初级保健中肠易激综合征的饮食或药物治疗:DOMINO研究——一项由比利时健康照护知识中心(KCE试验项目)与罗马基金会研究所支持的随机试验
在初级保健肠易激综合征(IBS)患者中,比较智能手机低FODMAP饮食应用与奥替溴铵(OB)的疗效。459例患者随机接受8周OB(40mg每日三次)或饮食干预并随访24周。饮食组8周应答率显著高于OB组(71% vs 61%,p=0.03),罗马IV标准阳性亚组差异更明显(77% vs 62%,p=0.004);饮食组依从性94% vs OB组73%(p<0.001)。作者认为低FODMAP饮食应被视为初级保健IBS的一线治疗。
要点
- 初级保健IBS患者中,低FODMAP饮食应用8周应答率71%,显著高于奥替溴铵的61%。
- 罗马IV标准阳性亚组中饮食组应答率77%,显著高于OB组的62%。
- 饮食组依从性94%,显著高于OB组的73%。
核心结论
- 在初级保健IBS患者中,低FODMAP饮食应用在改善IBS症状方面优于解痉剂奥替溴铵。
- 作者认为低FODMAP饮食应被视为初级保健IBS的一线治疗。
研究设计与样本
- 随机对照试验,由初级保健医生招募IBS患者,随机分配至8周奥替溴铵(40mg每日三次)或饮食干预,随访24周。
- 共纳入459例初级保健IBS患者(年龄41±15岁,76%女性,70%符合罗马IV标准)。
- 比较所有患者及符合罗马IV标准亚组的IBS症状严重程度评分和应答者比例(改善≥50分)。
- 同时评估治疗疗效、生活质量、焦虑、抑郁、躯体症状严重程度(PHQ15、PHQ9)及治疗依从性,并分析应答预测因素。
主要发现
- 8周应答率饮食组为71%(155/218),OB组为61%(133/217),差异显著(p=0.03)。
- 罗马IV标准阳性亚组8周应答率饮食组为77%(118/153),OB组为62%(98/158),差异显著(p=0.004)。
- 饮食组依从性为94%(199/212),OB组为73%(148/202),差异显著(p<0.001)。
- 饮食组显著更高的应答率在4周时已出现(62%(132/213) vs 51%(110/215),p=0.02),且高症状应答在随访期间持续。
- 应答预测因素:饮食组为女性(OR=2.08,p=0.04),OB组为PHQ15(OR=1.10,p=0.02)。
临床怎么用
- 作者认为低FODMAP饮食应被视为初级保健IBS的一线治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Europe, IBS is commonly treated with musculotropic spasmolytics (eg, otilonium bromide, OB). In tertiary care, a low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet provides significant improvement. Yet, dietary treatment remains to be explored in primary care. We evaluated the effect of a smartphone FODMAP-lowering diet application versus OB on symptoms in primary care IBS. METHODS: IBS patients, recruited by primary care physicians, were randomised to 8 weeks of OB (40 mg three times a day) or diet and followed for 24 weeks. We compared IBS Symptom Severity Score and the proportion of responders (improvement ≥50 points) in all patients and the subgroup fulfilling Rome IV criteria (Rome+). We also evaluated treatment efficacy, quality of life, anxiety, depression, somatic symptom severity (Patient Health Questionnaire (PHQ15, PHQ9)) and treatment adherence and analysed predictors of response. RESULTS: 459 primary care IBS patients (41±15 years, 76% female, 70% Rome+) were randomised. The responder rate after 8 weeks was significantly higher with diet compared with OB (71% (155/218) vs 61% (133/217), p=0.03) and more pronounced in Rome+ (77% (118/153) vs 62% (98/158), p=0.004). Patients allocated to diet (199/212) were 94% adherent compared with 73% with OB (148/202) (p<0.001). The significantly higher response rate with diet was already observed after 4 weeks (62% (132/213) vs 51% (110/215), p=0.02) and a high symptom response persisted during follow-up. Predictors of response were female gender (OR=2.08, p=0.04) for diet and PHQ15 (OR=1.10, p=0.02) for OB. CONCLUSION: In primary care IBS patients, a FODMAP-lowering diet application was superior to a spasmolytic agent in improving IBS symptoms. A FODMAP-lowering diet should be considered the first-line treatment for IBS in primary care. TRIAL REGISTRATION NUMBER: NCT04270487.
引用
- Carbone F, Van den Houte K, Besard L, et al. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022. PMID: 35483886. doi:10.1136/gutjnl-2021-325821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。